Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
06
06
2024
revised:
13
08
2024
accepted:
27
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
aheadofprint
Résumé
The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or upper tract urothelial cancer (UTUC) according to specific eligibility criteria; positive results indicate therapy with immune checkpoint inhibitors or erdafitinib, respectively. The EAU guidelines recommend PD-L1 testing for subsequent adjuvant therapy in high-risk UC, and germline DNA sequencing in patients with UTUC positive for DNA mismatch repair alterations.
Identifiants
pubmed: 39266382
pii: S0302-2838(24)02573-9
doi: 10.1016/j.eururo.2024.08.033
pii:
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.